News
Outcomes Switching to Monotherapy: SEAM-RA Trial
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
ACR20 - Opening Day Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Best Imaging Techniques for non ANCA Vasculitis
Large vessel vasculitis (LVV) and CNS vasculitis are rare subsets of vasculitis. The challenges related to these diseases are well known to the rheumatologists who treat around the world.
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been glued to their monitors all day, viewing video, reading and listening to abstract presentations and I charged them to earmark those presentations were the “Best” they saw today. Below is the list of most often noted #ACRbest abstracts from Day 1.
Diagnostic Delay in Psoriatic Arthritis: What are the Consequences?
Despite increased awareness and better diagnostic modalities at hand, early diagnosis of psoriatic arthritis (PsA) still remains a huge unmet need.
Secukinumab in Psoriatic Arthritis Patients with Axial Disease
Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52.
Psoriasis to Psoriatic Arthritis: Interim Results of the PRESTO Study
Early diagnosis of arthritis improves outcomes and quality of life in patients with psoriasis. A longitudinal cohort study shows that the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.
Building an ACR Annual Meeting for the Whole World
For many rheumatologists around the world, coming to America was a pilgrimage of sorts. A long journey and an expensive exercise but a worthy one – a fundamentally human exchange of ideas, where the person next to you could be from Arkansas, Alberta, or Amsterdam, but equally from Argentina, Algeria, Azerbaijan, or even Australia. So how (dare I say, on earth) do we translate that to our electronic screens?
